Medlab Clinical Ltd. announced that it has been granted the required regulatory approvals (human research ethics and clinical trial registration) for undertaking observational clinical trials of NanaBisTM and NanoCBDTM to gather information on side effects and treatment success over a long-time frame. This is now implemented in a bid to accelerate necessary information, with two new studies approved. Current observational study, which now has approximately 1,200 patients, demonstrated positive tolerability in relation to: Use with important cancer therapies, Co-prescribed tolerance and efficacy, Pain reduction and sustainable improvement in quality of life, Overall medication reductions.

The new studies are designed to elicit adverse event information, dosing verses outcomes and ongoing cognitive assessment.